BioSkryb Genomics, Research Instruments Offering Single-cell Technologies To Singapore, Southeast Asia

KUALA LUMPUR, Aug 30 (Bernama) -- BioSkryb Genomics has announced a partnership with Research Instruments Pte Ltd, to distribute BioSkryb’s ResolveDNA and ResolveOME single cell amplification tools throughout Singapore and Southeast Asia.

Research Instruments (Everlife-RI) is part of Everlife Asia, an Asia-focused market access and distribution group with strong capabilities in life sciences, clinical diagnostics, and analytical instrumentation operating in seven countries across Asia.

“We look forward to working with Everlife-RI to bring the power of ResolveOME and ResolveDNA to more researchers and investigators in Southeast Asia and enable greater insights into how complex diseases function.

“Expanding into these critical markets will support scientific breakthroughs in research, diagnostics and treatments through increased access to the unmatched resolution of our single cell multiomics platforms,” said BioSkryb Genomics Chief Executive Officer (CEO), Suresh Pisharody in a statement.

Meanwhile, Everlife-Research Instruments CEO, Yeo Seok Hoon said: “BioSkryb’s single cell amplification tools offer an unprecedented multiomic view at single-cell resolution, and we look forward to working with them to increase access to these powerful solutions throughout Southeast Asia.”

BioSkryb’s ResolveDNA genome amplification technology enables researchers to accurately examine whole genomes, whole exomes, and low-input DNA samples from single cells to reveal novel insights on the molecular drivers of disease.

ResolveOME is a first of its kind multiomic solution that combines whole genome or exome analysis with whole transcriptome analysis within each individual cell in an integrated workflow and can help investigators explore complex multiomic datasets at scale.

Powered by BioSkryb’s patented primary template-directed amplification (PTA) technology, ResolveOME and ResolveDNA dramatically increase genomic coverage to 97 per cent.

Headquartered in Durham, North Carolina, the United States, BioSkryb Genomics is a rapidly growing organisation that is transforming single cell molecular discovery and analysis.

-- BERNAMA